Saturday, February 28, 2015

Roth starts Cortendo AB at buy

Roth starts Cortendo AB at buy

February 27, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Cortendo AB (NOTC:CORT; OTC:CRTOF) with a “buy” rating and price target of $3. The stock closed at 97 cents on Thursday. Cortendo is conducting a global registration study with its lead asset COR-003, for the treatment of Cushing’s disease, which is caused by a corticotroph tumor of the […]

NOVADAQ posts record revenues in Q4

NOVADAQ posts record revenues in Q4

February 26, 2015 by · Leave a Comment 

Tweet NOVADAQ (NASDAQ:NVDQ; TSX:NDQ) has reported record revenues of $13.0 million for Q4-2014, an increase of 21% from $10.7 million in the fourth quarter of 2013, despite an approximate $2 million shortfall from SPY Elite sales by its former partner, LifeCell.  For all of 2014, the company reported revenue of $46.6-million, an increase of 33% from $35-million […]

Dipexium passes 25% enrollment in Locilex Phase 3s

Dipexium passes 25% enrollment in Locilex Phase 3s

February 25, 2015 by · Leave a Comment 

Tweet Dipexium Pharmaceuticals’ (NASDAQ:DPRX) two pivotal Phase 3 clinical trials, known as OneStep-1 and OneStep-2, have passed the 25% enrollment milestone, in the aggregate, with each study having enrolled nearly the same number of patients. The OneStep Phase 3 clinical trials are being conducted under a FDA from the FDA for evaluation of Locilex (pexiganan cream 0.8%), […]

Highland starts Columbia Labs at buy

Highland starts Columbia Labs at buy

February 25, 2015 by · Leave a Comment 

Tweet Highland Research Advisors has initiated coverage of Columbia Laboratories (NASDAQ:CBRX) with a “buy” rating and price target of $14. The stock closed at $6.05 on Tuesday. Columbia is focused on developing products to address the healthcare needs of women and has received FDA approval for six products, including Crinone, a gel containing progesterone that […]

Roth starts Viralytics at buy

Roth starts Viralytics at buy

February 25, 2015 by · Leave a Comment 

Tweet Roth Capital Markets has launched coverage of Viralytics (ASX:VLA; OTCQX:VRACY) with a “buy” rating and price target of $3.84 (Australian). The company’s lead drug candidate, CAVATAK, has delivered encouraging data in metastatic melanoma and is in expansion studies in multiple tumor types, writes analyst Joseph Pantginis. “We believe this oncolytic virus’ two pronged-mechanism of […]

Ciclofilin gets Japanese patent for inhibitor drugs

Ciclofilin gets Japanese patent for inhibitor drugs

February 24, 2015 by · Leave a Comment 

Tweet Closely-held Ciclofilin Pharmaceuticals has been issued a patent in Japan for its cyclophilin inhibitor drugs entitled, “Nonimmunosuppressive Cyclosporine Analogue Molecules.” The company’s lead molecule, CPI-431-32, is a candidate medicine designed to target and inhibit a host cellular enzyme known as cyclophilin A, which is responsible for activation of viral proteins critical for the life […]

Stifel starts Tracon Pharma at buy

Stifel starts Tracon Pharma at buy

February 24, 2015 by · Leave a Comment 

Tweet Stifel has launched coverage of Tracon Pharmaceuticals (NASDAQ:TCON) with a “buy” rating and $16 target price, saying the company predominantly develops cancer drugs that make other cancer drugs work better by blocking escape pathways. The stock closed at $10.15 on Monday. Antiangiogenic drugs are used throughout oncology and increasingly in other diseases, including ophthalmology, […]

Canaccord starts Avinger at buy

Canaccord starts Avinger at buy

February 24, 2015 by · Leave a Comment 

Tweet Canaccord Genuity has initiated coverage of Avinger (NASDAQ:AVGR) with a “buy” rating and price target of $18. The stock closed at $10.66 on Monday. “Avinger checks the most important boxes that we look for in a small-cap med-tech growth stock,” writes analyst Jason Mills. He said Avinger targets a large, under-penetrated and growing addressable […]

Leerink starts Ascendis Pharma at outperform

Leerink starts Ascendis Pharma at outperform

February 23, 2015 by · Leave a Comment 

Tweet Leerink Partners has launched coverage of Ascendis Pharma (NASDAQ:ASND) with an “outperform” rating a $30 price target. The stock closed at $19.34 on Friday. “We believe that the company’s proprietary TransCon prodrug technology is broadly applicable to developing longer acting versions of protein, peptide, and small molecule therapeutics,” writes analyst Joseph Schwartz. The TransCon […]

Roth starts Zosano Pharma at buy

Roth starts Zosano Pharma at buy

February 23, 2015 by · Leave a Comment 

Tweet Roth Capital Partners has initiated coverage of Zosano Pharma (NASDAQ:ZSAN) with a “buy” rating and price target of $20. The stock closed at $11.09 on Friday. Zosano Pharma has a microneedle “patch” platform that provides injection-like results with a more tolerable delivery vehicle. “The impetus for our buy rating is the potential of the […]

Next Page »

Email Newsletters with Constant Contact
Google+